JP2013504543A - 二環ヘテロアリール類のエーテル誘導体 - Google Patents

二環ヘテロアリール類のエーテル誘導体 Download PDF

Info

Publication number
JP2013504543A
JP2013504543A JP2012528376A JP2012528376A JP2013504543A JP 2013504543 A JP2013504543 A JP 2013504543A JP 2012528376 A JP2012528376 A JP 2012528376A JP 2012528376 A JP2012528376 A JP 2012528376A JP 2013504543 A JP2013504543 A JP 2013504543A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
amino
pyrrolo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504543A5 (enExample
Inventor
チェン・ベイ
ロビン・アレック・フェアハースト
アンドレアス・フレールスハイマー
パスカル・フュレ
ヴィト・グアニャーノ
ソンチュン・ジャン
ウェンシュオ・ル
トーマス・エイチ・マーシルジュ
クライブ・マッカーシー
ピエール−イブ・ミシェリー
フレデリック・シュタウファー
シュテファン・シュトゥッツ
アンドレア・ファウペル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of JP2013504543A publication Critical patent/JP2013504543A/ja
Publication of JP2013504543A5 publication Critical patent/JP2013504543A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2012528376A 2009-09-10 2010-09-10 二環ヘテロアリール類のエーテル誘導体 Pending JP2013504543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24118209P 2009-09-10 2009-09-10
US61/241,182 2009-09-10
PCT/EP2010/063334 WO2011029915A1 (en) 2009-09-10 2010-09-10 Ether derivatives of bicyclic heteroaryls

Publications (2)

Publication Number Publication Date
JP2013504543A true JP2013504543A (ja) 2013-02-07
JP2013504543A5 JP2013504543A5 (enExample) 2013-10-24

Family

ID=43511862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528376A Pending JP2013504543A (ja) 2009-09-10 2010-09-10 二環ヘテロアリール類のエーテル誘導体

Country Status (12)

Country Link
US (1) US20120165310A1 (enExample)
EP (1) EP2475668A1 (enExample)
JP (1) JP2013504543A (enExample)
KR (1) KR20120093867A (enExample)
CN (1) CN102596963A (enExample)
AU (1) AU2010294209A1 (enExample)
BR (1) BR112012005400A2 (enExample)
CA (1) CA2773661A1 (enExample)
EA (1) EA201200471A1 (enExample)
IN (1) IN2012DN02139A (enExample)
MX (1) MX2012002997A (enExample)
WO (1) WO2011029915A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536716A (ja) * 2015-12-02 2018-12-13 アストライア セラピューティクス， エルエルシーＡｓｔｒａｅａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ ピペリジニルノシセプチン受容体化合物
US11827617B2 (en) 2015-12-02 2023-11-28 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
CN103958510B (zh) 2011-10-03 2016-10-19 北卡罗来纳大学教堂山分校 用于治疗癌症的吡咯并嘧啶化合物
US9458162B2 (en) * 2012-01-31 2016-10-04 Nanjing Allgen Pharma Co. Ltd. Cyclic molecules as bruton's tyrosine kinase inhibitors
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
BR112014028424A2 (pt) 2012-05-22 2018-04-24 Univ North Carolina Chapel Hill compostos de pirimidina para o tratamento de câncer
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
CA2945128A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN106008527B (zh) 2016-06-29 2018-05-15 四川大学华西医院 吡唑并[3,4-d]嘧啶衍生物
CN107098909B (zh) * 2017-05-19 2019-02-22 四川大学华西医院 烷氧端基寡peg修饰的氨基嘧啶衍生物及抗肿瘤应用
CA3169649A1 (en) 2020-01-30 2021-08-05 The Regents Of The University Of California Strad-binding agents and uses thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2007503450A (ja) * 2003-08-25 2007-02-22 アムジエン・インコーポレーテツド 置換２，３−ジヒドロ−１ｈ−イソインドル−１−オン誘導体及び使用方法
JP2007509060A (ja) * 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
US5869485A (en) 1994-09-29 1999-02-09 Novartis Finance Corp. Pyrrolo 2,3-d!pyrimidines and their use
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ATE212993T1 (de) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
GB9516842D0 (en) 1995-08-17 1995-10-18 Ciba Geigy Ag Various acylated oligopeptides
GB9517060D0 (en) 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO1997032879A1 (de) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
JP4837864B2 (ja) 2000-02-09 2011-12-14 ノバルティス アーゲー 血管形成および／またはｖｅｇｆ受容体チロシンキナーゼを阻害するピリジン誘導体
JP4175115B2 (ja) 2001-05-11 2008-11-05 和光純薬工業株式会社 フッ素置換トリフェニルスルホニウム塩
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CN1960993A (zh) 2004-04-02 2007-05-09 Osi制药公司 6,6－双环取代的杂双环蛋白激酶抑制剂
JP2008521790A (ja) 2004-11-29 2008-06-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌剤としてのチアゼピンオキサゾリジノン
TW200730529A (en) 2005-12-07 2007-08-16 Osi Pharm Inc Process to prepare substituted imidazopyrazine compounds
US20100298286A1 (en) 2007-12-20 2010-11-25 Novartis Ag Organic Compounds
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2007503450A (ja) * 2003-08-25 2007-02-22 アムジエン・インコーポレーテツド 置換２，３−ジヒドロ−１ｈ−イソインドル−１−オン誘導体及び使用方法
JP2007509060A (ja) * 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536716A (ja) * 2015-12-02 2018-12-13 アストライア セラピューティクス， エルエルシーＡｓｔｒａｅａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ ピペリジニルノシセプチン受容体化合物
JP7011596B2 (ja) 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US11827617B2 (en) 2015-12-02 2023-11-28 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
USRE49825E1 (en) 2015-12-02 2024-02-06 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds

Also Published As

Publication number Publication date
MX2012002997A (es) 2012-08-01
WO2011029915A1 (en) 2011-03-17
IN2012DN02139A (enExample) 2015-08-07
BR112012005400A2 (pt) 2016-04-05
US20120165310A1 (en) 2012-06-28
AU2010294209A1 (en) 2012-03-29
EA201200471A1 (ru) 2012-10-30
CN102596963A (zh) 2012-07-18
CA2773661A1 (en) 2011-03-17
EP2475668A1 (en) 2012-07-18
KR20120093867A (ko) 2012-08-23

Similar Documents

Publication Publication Date Title
JP2013504543A (ja) 二環ヘテロアリール類のエーテル誘導体
US11028093B2 (en) 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
CA2945151C (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
US12264156B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
US20240317721A1 (en) Pyrazolyl derivatives as inhibitors of the kras mutant protein
TWI866258B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
TW202334138A (zh) 癌症治療方法
EA022355B1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
KR20190069529A (ko) 유비퀴틴 특이적 프로테아제 7의 억제제로서 피페리딘 유도체
TW201619159A (zh) 吡咯并［２，３－ｄ］嘧啶衍生物
US20220235048A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
US20240228506A1 (en) Ripk1 inhibitors and methods of use
EP3782997A1 (en) Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
US20240059698A1 (en) Heteroaryl compounds as egfr inhibitors and their uses
WO2025240582A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
US20120289501A1 (en) Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
EP3313397A1 (en) Purine inhibitors of human phosphatidylinositol 3-kinase delta
CA3195035A1 (en) Covalent egfr inhibitors and methods of use thereof
JP2014507465A (ja) フルオロフェニル二環式ヘテロアリール化合物
HK1238236B (en) 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
HUE025203T2 (en) CDK4 / 6 inhibitor pyrrolopyrimidine compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150210